D6M Stock Overview
A molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
genedrive plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0075 |
| 52 Week High | UK£0.11 |
| 52 Week Low | UK£0.002 |
| Beta | -0.038 |
| 11 Month Change | -48.28% |
| 3 Month Change | 66.67% |
| 1 Year Change | -84.85% |
| 33 Year Change | -96.65% |
| 5 Year Change | n/a |
| Change since IPO | -99.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| D6M | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -6.3% | -2.6% | -1.0% |
| 1Y | -84.8% | 0.9% | 12.8% |
Return vs Industry: D6M underperformed the German Life Sciences industry which returned 0.9% over the past year.
Return vs Market: D6M underperformed the German Market which returned 12.8% over the past year.
Price Volatility
| D6M volatility | |
|---|---|
| D6M Average Weekly Movement | 47.7% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: D6M's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: D6M's weekly volatility has decreased from 81% to 48% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 43 | Gino Miele | www.genedriveplc.com |
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive system, a rapid thermocycler and signal detection system and semi- automated system used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings. It also offers Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of HCV infection prior to drug administration, pathogen detection of biological military threats and a point-of-care for COVID-19 detection system for use in areas, such as healthcare, workplace screening, travel requirements, and confirmation of antigen tests.
genedrive plc Fundamentals Summary
| D6M fundamental statistics | |
|---|---|
| Market cap | €11.83m |
| Earnings (TTM) | -€5.97m |
| Revenue (TTM) | €324.64k |
36.4x
P/S Ratio-2.0x
P/E RatioIs D6M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D6M income statement (TTM) | |
|---|---|
| Revenue | UK£272.00k |
| Cost of Revenue | UK£3.81m |
| Gross Profit | -UK£3.54m |
| Other Expenses | UK£1.46m |
| Earnings | -UK£5.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0092 |
| Gross Margin | -1,301.47% |
| Net Profit Margin | -1,837.50% |
| Debt/Equity Ratio | 0% |
How did D6M perform over the long term?
See historical performance and comparison